Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986263 in Hepatic Impairment
NCT04225936Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of ND-L02-s0201 in Liver Fibrosis (LF) and Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration, Area under the serum concentration-time curve from time zero to last quantifiable concentration and 4 more. Started Jan 2020; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
Liver Fibrosis (LF)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04225936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225936.